Introduction
============

The prevalence of chronic obstructive pulmonary disease (COPD) is expected to increase globally.[@b1-copd-9-563],[@b2-copd-9-563] There is significant underdiagnosis of COPD in Japan, partly because spirometry testing is limited[@b3-copd-9-563] and symptoms appear progressively, becoming obvious only when lung function is already significantly impaired.[@b4-copd-9-563] Previous data have shown that spirometry screening during medical checkups can identify many patients with COPD who are not aware of this disease.[@b5-copd-9-563]

COPD is associated with increased risk of cardiovascular disease (CVD) and, in subjects with CVD, the coexistence of COPD is associated with raised morbidity, including a worsening of symptoms and more frequent hospitalizations.[@b6-copd-9-563],[@b7-copd-9-563],[@b8-copd-9-563] In addition, cardiovascular deaths are a significant cause of mortality in COPD patients.[@b9-copd-9-563]

Surveys have been performed to look at the prevalence of COPD in patients consulting medical institutions specializing in circulatory diseases. In Spain, airflow limitation was detected in 19% of patients with CVD.[@b10-copd-9-563] In Japan, from patients consulting the cardiovascular department of a university hospital, the prevalence of airflow limitation ranged from 10%--25%, depending on the primary conditions of the sampled patients.[@b11-copd-9-563],[@b12-copd-9-563] However, the possibility of a significant risk of the comorbidity of COPD and CVD is not widely accepted in Japan.

The combination of COPD with CVD is known to be associated with poorer prognosis,[@b7-copd-9-563]--[@b9-copd-9-563] largely attributed to increased systemic inflammation.[@b13-copd-9-563] Observational data have suggested that slowing COPD progression may help to reduce cardiovascular morbidity and mortality, which are themselves associated with more severe pulmonary symptoms.[@b14-copd-9-563] Exacerbations of COPD have been demonstrated to increase the risk of myocardial infarction and stroke,[@b15-copd-9-563] and COPD patients with CVD have significantly higher risk of COPD exacerbations and increased costs than COPD patients without CVD.[@b16-copd-9-563] Therefore, there is a good rationale for case-finding for COPD, in order to manage the disease as early as possible, prevent exacerbations, and reduce the risk of cardiovascular events.[@b17-copd-9-563]

The aim of this study was to determine the proportion of Japanese patients with a smoking history being treated for cardiovascular disease who have concurrent airflow limitation compatible with COPD. A secondary objective was to test whether the usage of respiratory function tests performed in the clinic influenced the diagnosis rate of COPD in patients identified with airflow limitation.

Methods
=======

Study design
------------

This study was a multicenter prospective observational study conducted at 17 clinics in Japan; in consecutive outpatients with a smoking history who routinely visited the clinic for their CVD. All patients gave written consent to participate in the study. Patients who were ≥40 years old and had a smoking history of ≥10 pack-years were enrolled in the study. Patients with hypertension were required to have received drug therapy for at least 1 year to be included. Any patient who had difficulty in performing spirometry on the day of the study visit, due to an acute respiratory infection, was required to return when the infection had resolved without the use of bronchodilator. Patients diagnosed with bronchial asthma were excluded.

Assessments were made at a single visit. Patients were asked to complete the COPD Assessment Test (CAT) questionnaire[@b18-copd-9-563] and a pulmonary function test, using a handheld spirometer: Hi-Checker (Takara Tsusho Co, Ltd, Tokyo, Japan) or Vitalograph (Vitalograph Inc., Lenexa, KS, USA). Forced expiratory volume in 1 second (FEV~1~), and in 6 seconds (FEV~6~) was measured prior to bronchodilator use. A predicted FEV~1~ value was calculated according to the formula used by the Lung Physiology Committee of the Japanese Respiratory Society.[@b19-copd-9-563] Airflow limitation was defined as FEV~1~/FEV~6~ ratio \<0.73. The FEV~1~/FEV~6~ ratio can be used as a valid alternative for FEV~1~/forced vital capacity (FVC) in the diagnosis of airway obstruction.[@b20-copd-9-563] Demography and details of concurrent diseases and medications were collected. Chronic bronchitis was defined as the presence of sputum for at least 3 months of the year, for more than 2 consecutive years.

Analysis
--------

The primary analysis set was the per protocol population. Study centers were stratified into three subsets based on the usage of pulmonary function tests. This was decided at the discretion of the cardiologists who participated in the study. Data analyses were performed for each subset. The subsets were classified as centers that performed pulmonary function tests often (≥10 times/month), less often (2--10 times/month), and seldom (\<2 times/month). A stratified analysis was performed based on demographic and other baseline characteristics. The mean values and 95% confidence intervals were calculated for FEV~1~, FEV~6~, and percentage of predicted FEV~1~ and FEV~1~/FEV~6~ values. Differences between groups were statistically analyzed by the chi-squared test. A *P*-value \<0.05 was considered statistically significant.

Results
=======

A total of 1,001 subjects were enrolled in the study. The study population consisted of 995 subjects for whom spirometry data and CAT assessment were available; six patients were removed due to a protocol violation or an inappropriate spirometry procedure.

The baseline demographics are shown in [Table 1](#t1-copd-9-563){ref-type="table"}. The mean age of the study population was 66.6±10.0 years, and the majority of patients were male (95.5%). Hypertension was the most common CVD, which was reported in 74.0% of patients -- the second highest CVD being arrhythmia (20.1%).

The prevalence of airflow limitation in this study was 27.0% (n=269). Of these, 87.7% (n=236) did not have a previous diagnosis of COPD ([Table 2](#t2-copd-9-563){ref-type="table"}). At the discretion of the consulting cardiologist centers were grouped by their usage of lung function tests. Four sites were classed as "often" (n=184 patients), three sites as "less often" (n=182 patients), and ten sites as "seldom" (n=629 patients). The prevalence of airflow limitation, split by the usage of lung function test, shows that even at sites categorized as "often", the level of undiagnosed COPD was high. But it was lower than at the sites classified as "seldom" ([Table 2](#t2-copd-9-563){ref-type="table"}).

The mean percentage of predicted FEV~1~ of the total study population was 62.5%±17.8%. Compared against the Global initiative for chronic Obstructive Lung Disease (GOLD) classification[@b26-copd-9-563] (the majority of patients having an FEV~1~ between 50%--79%; GOLD Grade 2), 20% of patients had lung function less than 50% of predicted FEV~1~. The values in this study are prebronchodilator, not postbronchodilator (as in GOLD) ([Figure 1](#f1-copd-9-563){ref-type="fig"}).

The demographic characteristics of patients who had airflow limitation, or did not, are shown in [Table 3](#t3-copd-9-563){ref-type="table"}. In the subjects with airflow limitation, significant differences were observed, with lower body mass index, greater age, more chronic bronchitic symptoms, and higher CAT score. There was no significant difference in the number of patients between airflow limitation and no airflow limitation, within the CVDs of ischemic heart disease, chronic heart failure, and arrhythmias ([Table 3](#t3-copd-9-563){ref-type="table"}). Percentages of patients with airflow limitation in each CVD are shown in [Table 4](#t4-copd-9-563){ref-type="table"}.

Discussion
==========

Airflow limitation compatible with COPD was present in 27.0% of outpatients with CVD and a history of smoking, with almost all of them being undiagnosed prior to this study. This prevalence estimate is in agreement with previous studies, which have reported that the prevalence of COPD is in the range 12%--34% amongst patients with coronary artery disease.[@b10-copd-9-563],[@b21-copd-9-563]--[@b24-copd-9-563] In a study conducted by Soriano et al,[@b10-copd-9-563] the prevalence of airway limitation was 19.2% in subjects with CVD. It was not a Japanese study and lacked criteria for age and smoking history; the prevalence was lower than our study result. In studies conducted by Wada et al[@b11-copd-9-563] and Yamasaki et al[@b12-copd-9-563] in Japan, the prevalence of airflow limitation in patients with CVD was also lower (10.9% and 22.6%, respectively). These studies were both conducted on single sites. In the Wada et al study, there was good collaboration between cardiology and respirology. Additionally, although this study excluded subjects \<40 years old, there were no entry criteria for smoking.[@b11-copd-9-563] In the Yamasaki et al study there were no entry criteria for age or smoking.[@b12-copd-9-563]

In our study, the presence of COPD was shown to increase with age, as expected, but undiagnosed airflow limitation was also seen in patients as young as 40--49 years. There were statistically significant differences observed between patients with and without airflow limitation, for parameters including age, smoking pack-years, CAT score, chronic bronchitis, and body mass index. In patients with chronic bronchitic symptoms, 33.5% had airflow limitation, suggesting that this history may be a useful predictor of COPD amongst patients with CVD. This has also been demonstrated recently in another study, which showed that underdiagnosis of COPD was particularly a problem in younger men with chronic bronchitic symptoms -- a phenotype which is not usually recognized as COPD in Japan[@b25-copd-9-563] because the Japanese COPD phenotype tends to be seen as: older, more emphysemic, less exacerbations, and less chronic bronchitic. Increased risk of COPD was associated with all CVDs; in our study, there was no significant difference in the number of patients with or without airflow limitation, with the CVDs of ischemic heart disease, coronary heart failure, and arrhythmias.

In this study, when patients were categorized using the GOLD criteria for airflow limitation,[@b26-copd-9-563] the majority (55%) were in GOLD Grade 2, but 20% of patients had an FEV~1~ less than 50% of predicted, showing that even patients with severe-to-very-severe airflow limitation had not been previously diagnosed. Patients with COPD categorized as GOLD Grade 1 show an increased risk of mortality, so it is important to find and treat these undiagnosed patients.[@b27-copd-9-563]

The prevalence of patients with airflow limitation was spread fairly evenly between the centers (split by the usage of lung function testing). As expected, there were a higher number of patients with a prior diagnosis of COPD in the centers with greater use of spirometry, compared with the centers where its use was "seldom". But even those centers classed as having using spirometry "often" had a high number of CVD patients with undiagnosed COPD.

Patients with CVD and a smoking history are at increased risk of airway limitation, and should benefit from lung function screening, as they have been reported to be frequently asymptomatic.[@b28-copd-9-563] The mean CAT score in patients with airflow limitation was a little higher (8.3±6.5), compared with patients with no airflow limitation (6.4±5.4). The score for patients with airflow limitation was lower than for patients with diagnosed COPD,[@b18-copd-9-563] but it should be appreciated that most of the patients in our study had not been diagnosed with COPD -- presumably, because their symptoms were inconclusive. Support for this interpretation comes from Miravitlles et al,[@b29-copd-9-563] who showed that St George's Respiratory Questionnaire scores in people identified as having COPD on screening were significantly lower than in those with a prior COPD diagnosis, and only a little higher than the normal range. CAT scores in CVD patients were similar to those seen in Japanese workers with undiagnosed airflow limitation, identified in a screening spirometry study.[@b30-copd-9-563]

There are some limitations of this study. We recruited patients older than \>40 years old with a smoking history; smoking is not prevalent among Japanese women of this age group. Further study is needed to confirm the prevalence of COPD among nonsmokers.

Conclusion
==========

Airflow limitation compatible with COPD was seen in a quarter of outpatients with CVD in our study, with almost all of them being undiagnosed. This suggests that it is important to look routinely for COPD in CVD patients \>40 years old with a history of smoking, as the combination of COPD with CVD is known to be associated with poorer prognosis.
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###### 

Baseline demographics of the per protocol population

                                  n=995
  ------------------------------- --------------
  Mean age (SD); years            66.6 (9.96)
  Male; n (%)                     950 (95.5)
  Current smoker; n (%)           273 (27.4)
  Ex-smoker; n (%)                722 (72.6)
  Smoking pack-years; mean (SD)   43.1 (26.08)
  BMI; mean (SD)                  24.64 (3.48)
  Diagnosed COPD; n (%)           48 (4.8)
  Chronic sputum; n (%)           203 (20.4)
  FEV~1~; mean (SD)               2.29 (0.70)
  FEV~6~; mean (SD)               2.97 (0.79)
  CAT score; mean (SD)            6.9 (5.8)
  Myocardial infarction; n (%)    158 (15.9)
  Hypertension; n (%)             736 (74.0)
  Chronic heart failure; n (%)    113 (11.4)
  Angina; n (%)                   192 (19.3)
  Arrhythmia; n (%)               200 (20.1)
  Stroke; n (%)                   48 (4.8)
  Arteriosclerosis; n (%)         24 (2.4)
  Other CVD; n (%)                187 (18.8)
  1 CVD; n (%)                    576 (57.9)
  2 CVD; n (%)                    253 (25.4)
  3 CVD; n (%)                    108 (10.9)
  4 CVD or more; n (%)            58 (5.8)

**Abbreviations:** BMI, body mass index; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation; CAT, COPD assessment test; FEV~1~, forced expiratory volume in 1 second; FEV~6~, forced expiratory volume in 6 seconds.

###### 

The number of patients with airflow limitation and a previous diagnosis of COPD

                                                                                 Total subjects in per protocol population (n=995)   
  ------------------------------------------------------------------------------ --------------------------------------------------- -------
  Total                                                                          27.0%                                               12.3%
  **Split by age range**                                                                                                             
  40--49 years                                                                   5.1%                                                0%
  50--59 years                                                                   16.6%                                               3.8%
  60--69 years                                                                   21.4%                                               12.5%
  \>70 years                                                                     39.4%                                               13.8%
  **Lung function tests performed[\*](#tfn2-copd-9-563){ref-type="table-fn"}**                                                       
  Often                                                                          23.4%                                               14.0%
  Less often                                                                     25.3%                                               15.2%
  Seldom                                                                         28.6%                                               11.1%

**Note:**

Split at the discretion of the consulting cardiologist.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Characteristics of patients with and without airflow limitation (prevalence of COPD)

                                               Airflow limitation (n=269)   No airflow limitation (n=726)   Airway limitation versus no airway limitation[\*](#tfn4-copd-9-563){ref-type="table-fn"}
  -------------------------------------------- ---------------------------- ------------------------------- ------------------------------------------------------------------------------------------
  Age, mean (SD)                               71.0 (8.8)                   65.0 (9.8)                      *P*\<0.001
  Males, n (%)                                 258 (96%)                    692 (95%)                       *P*=0.689
  Current smoker; n (%)                        76 (28.3%)                   197 (27.1%)                     *P*=0.726
  Ex-smoker; n (%)                             193 (71.7%)                  529 (72.9%)                     
  Pack-years; mean (SD)                        48.6 (26.2)                  41.1 (25.8)                     *P*\<0.001
  BMI; mean (SD)                               23.3 (3.1)                   25.1 (3.4)                      *P*\<0.001
  Diagnosis of COPD; n (%)                     33 (12.3%)                   15 (2%)                         *P*\<0.001
  Positive chronic bronchitis criteria n (%)   68 (25.3%)                   135 (18.6%)                     *P*=0.020
  FEV~1~; mean (SD)                            1.776 (0.64)                 2.483 (0.62)                    *P*\<0.001
  FEV~6~; mean (SD)                            2.789 (0.81)                 3.034 (0.77)                    *P*\<0.001
  CAT score; mean (SD)                         8.3 (6.5)                    6.4 (5.4)                       *P*\<0.001
  **CV history**                                                                                            
  Myocardial infarction                        41 (15.2%)                   117 (16.1%)                     
  Hypertension                                 207 (77.0%)                  529 (72.9%)                     
  Chronic heart failure                        34 (12.6%)                   79 (10.9%)                      
  Angina                                       46 (17.1%)                   146 (20.1%)                     
  Arrhythmia                                   59 (21.9%)                   141 (19.4%)                     
  Stroke                                       18 (6.7%)                    30 (4.1%)                       
  Arteriosclerosis                             9 (3.3%)                     15 (2.1%)                       
  Other CVD                                    48 (17.8%)                   139 (19.1%)                     
  Hypertension only                            110 (40.9%)                  293 (40.4%)                     

**Note:**

Chi-squared test.

**Abbreviations:** CV, cardiovascular; CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; SD, standard deviation; CAT, COPD assessment test; FEV~1~, forced expiratory volume in 1 second; FEV~6~, forced expiratory volume in 6 seconds.

###### 

The number of patients with airflow limitation by CV history

  CV history              n     Airflow limitation n (%)
  ----------------------- ----- --------------------------
  Myocardial infarction   158   41 (25.9%)
  Hypertension            736   207 (28.1%)
  Chronic heart failure   113   34 (30.1%)
  Angina                  192   46 (24.0%)
  Arrhythmia              200   59 (29.5%)
  Stroke                  48    18 (37.5%)
  Arteriosclerosis        24    9 (37.5%)
  Other CVD               187   48 (25.7%)
  Hypertension only       403   110 (27.3%)

**Abbreviations:** CV, cardiovascular; CVD, cardiovascular disease.
